G1SK34:BVMF
Gsk Plc Bdr
48,55 BRL
0,00%
(0,00) 1D
14. okt., 16:56:00 GMT -3 · BRL
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za G1SK34 …
Odpri
47,15 BRL
Visoka
48,55 BRL
Nizka
47,15 BRL
Tržna kapitalizacija
73,67 mrd.
Povprečni promet
221,00
Promet
2,00
52-tedenski najvišji tečaj
63,24 BRL
52-tedenski najnižji tečaj
46,15 BRL
Št. izdanih delnic
4,32 mrd.
Št. zaposlenih
67 tis.
Odpri
47,15 BRL
Visoka
48,55 BRL
Nizka
47,15 BRL
Tržna kapitalizacija
73,67 mrd.
Povprečni promet
221,00
Promet
2,00
52-tedenski najvišji tečaj
63,24 BRL
52-tedenski najnižji tečaj
46,15 BRL
Št. izdanih delnic
4,32 mrd.
Št. zaposlenih
67 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
Dealroom
·
pred 7 urami
GSK to invest $800M in Pennsylvania, adding 300 jobs
GuruFocus
·
pred 11 urami
GSK PLC (GSK) Shares Surge 3.5% -- What GF Score of 77 Tells Inv
Reuters
·
pred 16 urami
GSK plans to cut up to 1,217 jobs in Belgium as it begins three-year restructuring plan
Stock Titan
·
pred 17 urami
At £17.3550 per ordinary share, dividend reinvestment adds to GSK (GSK) executives’ interests.
Profil
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Vizitka: Gsk Plc Bdr
Generalni direktorEmma Walmsley | Emma Walmsley
Št. zaposlenih66,8 tis.
Ustanovljeno27. dec. 2000
Sedež-
Sektor-
Spletno mestogsk.com